Contrasting Cardax (OTCMKTS:CDXI) & Surrozen (NASDAQ:SRZN)

Cardax (OTCMKTS:CDXI) and Surrozen (NASDAQ:SRZN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Valuation & Earnings

This table compares Cardax and Surrozen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardax	N/A	N/A	N/A	N/A	N/A
Surrozen	$3.48 million	70.59	-$242.03 million	($37.59)	-0.56

Cardax has higher earnings, but lower revenue than Surrozen.

Volatility & Risk

Cardax has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Cardax and Surrozen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardax	0	0	0	0	0.00
Surrozen	2	0	3	1	2.50

Surrozen has a consensus price target of $42.00, indicating a potential upside of 98.49%. Given Surrozen’s stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than Cardax.

Profitability

This table compares Cardax and Surrozen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardax	N/A	N/A	N/A
Surrozen	-4,810.50%	N/A	-154.08%

Institutional and Insider Ownership

66.6% of Surrozen shares are owned by institutional investors. 29.5% of Cardax shares are owned by insiders. Comparatively, 31.7% of Surrozen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Surrozen beats Cardax on 7 of the 10 factors compared between the two stocks.

About Cardax

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.